NEW YORK, NY--(Marketwire - Feb 7, 2012) - Biotech stocks are on fire in 2012. The iShares NASDAQ Biotechnology index is up more than 15 percent year-to-date as impressive earnings results have boosted investor optimism in the industry. According to BB B

Biotech companies are leaving no stone unturned in developing new and advanced medicines by focusing on R&D. In this article, I analyze key mid-cap biotech companies that sophisticated investors should keep an eye on in 2012. These companies have potenti

Oppenheimer (NYSE: OPY) boosted their price target on shares of AEterna Zentaris (NASDAQ: AEZS) from $4.00 to $5.00 in a research note issued on Wednesday. Separately, analysts at Rodman & Renshaw reiterated an “outperform” rating on shares of AEterna Ze

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (ARIA) today announced That their phase 2 clinical drug Ponatinib, a pan BCR-ABL inhibitor, has failed to meet it's primary safety endpoint goal. Dr, Harvey Berger, the company CEO of Ariad

AEZS) price target from $5 to $4 in a research report published today. Oppenheimer has an Outperform rating on AEterna Zentaris. In the report, Oppenheimer states, "Yesterday AEZS announced a new at-the-market ("ATM") financing for up to 10.4M shares. Th

As families and friends gather together for the holidays, the topics of conversation can vary widely from politics, current news events, and the most often discussed, investing. For those well informed investors who spend their time performing all the ne